Huadong Medicine's controlling shareholder adjusts share pledge status

China Grand Enterprises, Huadong Medicine's controlling shareholder, recently pledged 39,160,000 shares, representing 5.36% of its holdings and 2.23% of the company's total share capital. These pledges, serving as collateral for continued loans, are set to expire by November 6, 2025, or until the completion of the pledge release registration by both parties. The pledges were made to China Galaxy Securities Co., Ltd.

Concurrently, China Grand Enterprises released pledges on 40,370,000 shares. This included 19,850,000 shares (2.72% of holdings, 1.13% of total share capital) initially pledged on November 9, 2022, and 20,520,000 shares (2.81% of holdings, 1.17% of total share capital) pledged on May 17, 2023. Both releases concluded on November 7, 2025, with China Galaxy Securities Co., Ltd. as the original pledgee.

Following these adjustments, China Grand Enterprises' total pledged shares decreased from 143,880,000 to 142,670,000 shares, representing 19.52% of its holdings and 8.13% of Huadong Medicine's total share capital. The company clarified that these pledge changes do not pose a risk of forced liquidation or transfer and will not impact the company’s operations or governance.